var data={"title":"Lidocaine and menthol: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Lidocaine and menthol: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/764583?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=lidocaine-and-menthol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Lidocaine and menthol: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27004038\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>1st Relief Spray [OTC];</li>\n      <li>Aflexeryl-LC [OTC] [DSC];</li>\n      <li>Atendia [DSC];</li>\n      <li>AvaDERM [OTC];</li>\n      <li>AvaLin [OTC];</li>\n      <li>AvaLin-Rx [DSC];</li>\n      <li>ELenzaPatch [DSC];</li>\n      <li>Endoxcin [OTC];</li>\n      <li>K2K Pain Relieving [DSC];</li>\n      <li>LenzaGel [OTC];</li>\n      <li>LenzaPatch [OTC];</li>\n      <li>LevigoLT [OTC];</li>\n      <li>Lidenza;</li>\n      <li>Lidodextrapine [DSC];</li>\n      <li>LidoPatch Pain Relief [OTC];</li>\n      <li>Lidothol;</li>\n      <li>LidozenGel [OTC];</li>\n      <li>LidozenPatch [OTC];</li>\n      <li>Limencin [OTC];</li>\n      <li>Lorenza;</li>\n      <li>MaL Patch;</li>\n      <li>Mentho-Caine;</li>\n      <li>Mentholix [DSC];</li>\n      <li>Pain Relief [DSC];</li>\n      <li>Pain Relief [OTC] [DSC];</li>\n      <li>Prolida [OTC];</li>\n      <li>Provenza [DSC];</li>\n      <li>Puroxcin [OTC] [DSC];</li>\n      <li>Reciphexamine [DSC];</li>\n      <li>Releevia ML;</li>\n      <li>Relyyks [DSC];</li>\n      <li>Siterol [OTC];</li>\n      <li>Solmara [DSC];</li>\n      <li>Solmara [OTC] [DSC];</li>\n      <li>Synvexia;</li>\n      <li>Synvexia TC;</li>\n      <li>Terocin [OTC];</li>\n      <li>Veltrix;</li>\n      <li>Venia [OTC];</li>\n      <li>Zeruvia</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50511719\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Analgesic, Topical;</li>\n      <li>\n        Local Anesthetic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50511760\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anesthetic:</b> Topical:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>OTC products:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cream: Apply a thin film to the affected area 3 to 4 times daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gel, spray: Apply to affected areas &le;4 times daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patch:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Avalin: Apply patch to affected area &le;4 times daily. Patch may remain in place for up to 8 hours. Do not use for &gt;5 consecutive days.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">LidoPatch: Apply patch to affected area. Patch may remain in place for up to 12 hours (maximum: 1 patch/24 hours).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Lidothol: Apply patch to affected area. Patch may remain in place for 8 to 12 hours (maximum: 2 patches/24 hours).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Siterol: Apply patch to affected area. Patch may remain in place for up to 8 hours (maximum: 4 patches/24 hours). Do not use &gt;5 consecutive days.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Solmara, Terocin: Apply patch to affected area once or twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rx products:</b> Cream: Apply a thin film to the affected area 2 or 3 times daily.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50990317\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50987653\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50511775\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anesthetic:</b> Topical: <b>OTC products:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cream: Children &ge;2 years and Adolescents: Apply a thin film to the affected area 3 to 4 times daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Spray: Children &ge;2 years and Adolescents: Apply to affected areas &le;4 times daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Patch:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Avalin: Children &ge;2 years and Adolescents: Apply patch to affected area &le;4 times daily. Patch may remain in place for up to 8 hours. Do not use for longer than 5 consecutive days.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Lidothol: Children &ge;12 years and Adolescents: Apply patch to affected area. Patch may remain in place for 8 to 12 hours (maximum: 2 patches/24 hours).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Solmara, Terocin: Children &ge;12 years and Adolescents: Apply patch to affected area once or twice daily.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51159620\" class=\"block dorp drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51159621\" class=\"block dohp drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50511776\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27004039\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cream, External: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AvaDERM: Lidocaine 4% and menthol 1% (120 g) [contains cetearyl alcohol, propylene glycol, trolamine (triethanolamine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LevigoLT: Lidocaine 4% and menthol 1% (76.5 g) [paraben free; contains cetearyl alcohol, disodium edta]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Synvexia TC: Lidocaine 4% and menthol 1% (60 g) [contains cetyl alcohol, naproxen, trolamine salicylate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Veltrix: Lidocaine 4% and menthol 1% (120 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gel, External: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LenzaGel: Lidocaine 4% and menthol 1% (120 g) [contains brilliant blue fcf (fd&amp;c blue #1), polysorbate 80, tartrazine (fd&amp;c yellow #5), trolamine (triethanolamine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LidozenGel: Lidocaine 4% and menthol 1% (120 mL) [contains brilliant blue fcf (fd&amp;c blue #1), polysorbate 80, tartrazine (fd&amp;c yellow #5), trolamine (triethanolamine)]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, External: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mentho-Caine: Lidocaine 5% and menthol 8%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Liquid, External: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mentholix: Lidocaine 4% and menthol 1% (120 mL [DSC]) [contains propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1st Relief Spray: Lidocaine 4% and menthol 1% (118 mL) [contains sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Patch, External: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aflexeryl-LC: Lidocaine 4% and menthol 1% (15 ea [DSC]) [contains brilliant blue fcf (fd&amp;c blue #1), polysorbate 80, tartrazine (fd&amp;c yellow #5), trolamine (triethanolamine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Atendia: Lidocaine 4% and menthol 3% (15 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AvaLin: Lidocaine 4% and menthol 1% (15 ea) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AvaLin-Rx: Lidocaine 4% and menthol 1% (15 ea [DSC]) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ELenzaPatch: Lidocaine 4% and menthol 1% (15 ea [DSC]) [contains brilliant blue fcf (fd&amp;c blue #1), polysorbate 80, tartrazine (fd&amp;c yellow #5), trolamine (triethanolamine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endoxcin: Lidocaine 4% and menthol 1% (15 ea, 30 ea) [contains brilliant blue fcf (fd&amp;c blue #1), polysorbate 80, tartrazine (fd&amp;c yellow #5), trolamine (triethanolamine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">K2K Pain Relieving: Lidocaine 4% and menthol 4% (10 ea [DSC]) [contains edetate disodium, iodopropynyl butylcarbamate, methylparaben, polysorbate 80, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LenzaPatch: Lidocaine 4% and menthol 1% (5 ea) [contains brilliant blue fcf (fd&amp;c blue #1), polysorbate 80, tartrazine (fd&amp;c yellow #5), trolamine (triethanolamine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lidenza: Lidocaine 4% and menthol 1% (15 ea) [contains brilliant blue fcf (fd&amp;c blue #1), polysorbate 80, tartrazine (fd&amp;c yellow #5), trolamine (triethanolamine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lidodextrapine: Lidocaine 4% and menthol 1% (15 ea [DSC]) [contains brilliant blue fcf (fd&amp;c blue #1), polysorbate 80, tartrazine (fd&amp;c yellow #5), trolamine (triethanolamine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LidoPatch Pain Relief: Lidocaine 3.99 % and menthol 1.25% (3 ea) [contains disodium edta, iodopropynyl butylcarbamate, methylparaben, polysorbate 80, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LidoPatch Pain Relief: Lidocaine 3.6% and menthol 1.25% (3 ea) [contains disodium edta, methylparaben, polysorbate 80, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lidothol: Lidocaine 4.5% and menthol 5% (1 ea, 15 ea) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LidozenPatch: Lidocaine 4% and menthol 1% (5 ea) [contains brilliant blue fcf (fd&amp;c blue #1), polysorbate 80, tartrazine (fd&amp;c yellow #5), trolamine (triethanolamine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Limencin: Lidocaine 4% and menthol 4% (10 ea) [contains edetate disodium, iodopropynyl butylcarbamate, methylparaben, polysorbate 80, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lorenza: Lidocaine 4% and menthol 1% (15 ea) [contains edetate disodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MaL Patch: Lidocaine 4% and menthol 5% (15 ea) [contains disodium edta, iodopropynyl butylcarbamate, methylparaben, polysorbate 80, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pain Relief: Lidocaine 4% and menthol 1% (15 ea [DSC]); Lidocaine 5% and menthol 1% (15 ea [DSC]) [contains brilliant blue fcf (fd&amp;c blue #1), polysorbate 80, tartrazine (fd&amp;c yellow #5), trolamine (triethanolamine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Prolida: Lidocaine 4% and menthol 1% (15 ea) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Provenza: Lidocaine 4% and menthol 1% (15 ea [DSC], 30 ea [DSC], 60 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Puroxcin: Lidocaine 4% and menthol 1% (15 ea [DSC], 30 ea [DSC]) [contains brilliant blue fcf (fd&amp;c blue #1), polysorbate 80, tartrazine (fd&amp;c yellow #5), trolamine (triethanolamine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Reciphexamine: Lidocaine 4% and menthol 1% (15 ea [DSC]) [contains brilliant blue fcf (fd&amp;c blue #1), polysorbate 80, tartrazine (fd&amp;c yellow #5), trolamine (triethanolamine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Releevia ML: Lidocaine 4% and menthol 1% (15 ea) [contains brilliant blue fcf (fd&amp;c blue #1), polysorbate 80, tartrazine (fd&amp;c yellow #5), trolamine (triethanolamine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Relyyks: Lidocaine 4% and menthol 5% (15 ea [DSC]) [contains disodium edta, iodopropynyl butylcarbamate, methylparaben, polysorbate 80, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Siterol: Lidocaine 3.99% and menthol 1% (15 ea) [contains brilliant blue fcf (fd&amp;c blue #1), polysorbate 80, tartrazine (fd&amp;c yellow #5)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Solmara: Lidocaine 4% and menthol 5% (15 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Synvexia: Lidocaine 4% and menthol 1% (5 ea, 10 ea, 15 ea, 30 ea) [contains disodium edta, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Terocin: Lidocaine 4% and menthol 4% (10 ea) [contains edetate disodium, iodopropynyl butylcarbamate, methylparaben, polysorbate 80, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Venia: Lidocaine 4% and menthol 4% (10 ea) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zeruvia: Lidocaine 4% and menthol 1% (10 ea [DSC], 15 ea, 30 ea) [contains disodium edta, polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26974435\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50511790\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">For external use only; not for ophthalmic, oral, or genital use; do not use on open wounds, cuts, damaged or infected skin or on mucous membranes. Some products are not recommended for use with bandages; consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Patch: Clean and dry affected area prior to administration; remove protective film and apply. Wash hands after application. Avoid exposing application site to external heat sources (eg, heating pad, electric blanket, heat lamp, hot tub).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50511732\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anesthetic, topical:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>OTC products:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cream, gel, and spray: Temporary relief of pain and itching associated with minor burns and cuts, scrapes, sunburn, insect bites, or skin irritations.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patch: Temporary relief of mild to moderate muscles/joint aches and pains (eg, arthritis, simple backache, bursitis, tendonitis, muscle soreness/stiffness/strains, sprains, bruises); temporary relief of pain associated with minor cuts, scrapes, or skin irritations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>RX products: </b>Cream: Relief of abrasions, minor burns, insect bites, pain, pruritic eczemas, pruritus, soreness, and discomfort due to anal fissures, hemorrhoids, pruritus ani, pruritus vulvae, and similar conditions of the skin and mucous membranes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50540252\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Also see Lidocaine monograph.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Burning sensation, localized warm feeling, paresthesia (localized), stinging sensation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Localized erythema</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Localized edema</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50511736\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to lidocaine, menthol, local anesthetic of the amide type, or any component of the formulation; secondary bacterial infection at application site; traumatized mucosa.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50511737\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Local effects: Irritation, sensitivity, and/or infection may occur at the site of application; discontinue use and institute appropriate therapy if local effects occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acutely ill patients: Use with caution; acutely ill patients should be given reduced doses commensurate with their age and physical status.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Debilitated patients: Use with caution; debilitated patients should be given reduced doses commensurate with their age and physical status.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution; elderly patients should be given reduced doses commensurate with their age and physical status.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Use with caution; children should be given reduced doses commensurate with their age and physical status.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol: Some dosage forms may contain benzyl alcohol and/or sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&quot;gasping syndrome&quot;) in neonates; the &quot;gasping syndrome&quot; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggest that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol and/or benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (alad 1986; CDC 1984). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Topical patch: Avoid exposing application site to external heat sources (eg, heating pad, electric blanket, heat lamp, hot tub).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Self-medication (OTC use): When used for self-medication, discontinue use and contact health care provider if symptoms persist &gt;7 days, condition worsens or recurs, or if rash, irritation, or itching develops. Do not use on open wounds, cuts, damaged or infected skin; in the eyes, mouth, genitals; or any other mucous membranes. Do not use in large quantities, particularly over raw or blistered areas. Some products are not recommended for use with bandages; consult specific product labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27004238\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to individual components.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27004235\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=114508&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antiarrhythmic Agents (Class III): Lidocaine (Topical) may enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III). Antiarrhythmic Agents (Class III) may increase the serum concentration of Lidocaine (Topical). This mechanism specifically applies to amiodarone and dronedarone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: May increase the serum concentration of Lidocaine (Topical).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Disopyramide: May enhance the arrhythmogenic effect of Lidocaine (Topical). Disopyramide may increase the serum concentration of Lidocaine (Topical). Specifically, the unbound/free fraction of lidocaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when nitric oxide is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obeticholic Acid: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon Alfa-2b: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracaine (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vemurafenib: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors). Management: Consider alternatives to such combinations whenever possible, particularly if the CYP1A2 substrate has a relatively narrow therapeutic index.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50511733\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50511734\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted with this combination. See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50511735\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if lidocaine or menthol is present in breast milk following use of this preparation. The manufacturer recommends that caution be exercised when administering lidocaine/menthol to breastfeeding women. See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50511744\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lidocaine: Blocks both initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Menthol: Dilates the blood vessels, causing a sensation of coldness followed by an analgesic effect; relieves itching.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50511745\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27265721\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (LenzaGel External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4-1% (120 g): $484.51</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (LidozenGel External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4-1% (120 mL): $484.51</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch</b> (Endoxcin External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4-1% (15): $603.75</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch</b> (LenzaPatch External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4-1% (5): $210.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch</b> (LidoPatch Pain Relief External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3.6-1.25% (3): $6.23</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3.99-1.25% (3): $27.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch</b> (Lidothol External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4.5-5% (1): $49.67</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch</b> (LidozenPatch External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4-1% (5): $210.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch</b> (Venia External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4-4% (10): $421.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    1<sup>st</sup> Relief Spray (lidocaine and menthol) [prescribing information]. Los Angeles, CA: 1<sup>st</sup> Class Pharmaceuticals; May 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319. DOI: 10.1067/mpd.2001.116281<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-and-menthol-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-and-menthol-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    AvaDerm (lidocaine hydrochloride and menthol) [prescribing information]. Encino, CA: MAS Pharma; July 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    AvaLin (lidocaine and menthol) [prescribing information]. Burbank, CA: RxChange Co; January 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep. </i>1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-and-menthol-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-and-menthol-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics.</i> 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-and-menthol-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-and-menthol-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    LenzaGel (lidocaine hydrochloride and menthol) [prescribing information]. Glendale, CA: Pharmaceutica North America; June 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    LidoPatch Pain Relief (lidocaine and menthol) [prescribing information]. Elmhurst, IL: JAR Laboratories; received October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lidothol (lidocaine and menthol) [prescribing information]. Reno, NV: Terrain Pharmaceuticals; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-and-menthol-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-and-menthol-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Siterol (lidocaine hydrochloride and menthol) [prescribing information]. Los Angeles, CA: Binger Consulting Corporation; May 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solmara (lidocaine and menthol) [prescribing information]. Tampa, FL: Spring Hill Therapeutics; July 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Synvexia TC (lidocaine hydrochloride and menthol) [prescribing information]. Ripley, MS: Sterling Knight Pharmaceuticals; December 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Terocin (lidocaine and menthol) [prescribing information]. Los Angeles, CA: Alexso Inc; July 2017.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 114508 Version 19.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F27004038\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F50511719\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F50511760\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50990317\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50987653\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F50511775\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Pediatric)\" href=\"#F51159620\" class=\"outlineLink\">Dosing: Renal Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Pediatric)\" href=\"#F51159621\" class=\"outlineLink\">Dosing: Hepatic Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F50511776\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F27004039\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F26974435\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F50511790\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F50511732\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F50540252\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F50511736\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F50511737\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F27004238\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F27004235\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F50511733\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F50511734\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F50511735\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F50511744\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F50511745\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F27265721\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/114508|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=lidocaine-and-menthol-patient-drug-information\" class=\"drug drug_patient\">Lidocaine and menthol: Patient drug information</a></li></ul></div></div>","javascript":null}